Integration of Pathological Criteria and Immunohistochemical Evaluation for Invasive Lobular Carcinoma Diagnosis: Recommendations From the European Lobular Breast Cancer Consortium.

Autor:	De Schepper M; Department of Oncology, Laboratory for Translational Breast Cancer Research, KU Leuven, Leuven, Belgium; Department of Pathology, University Hospitals Leuven, UH Leuven, Leuven, Belgium., Koorman T; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., Richard F; Department of Oncology, Laboratory for Translational Breast Cancer Research, KU Leuven, Leuven, Belgium., Christgen M; Institute of Pathology, Hannover Medical School, Hannover, Germany., Vincent-Salomon A; Department of Pathology-Genetics_Immunology, Institut Curie, PSL Research University, Diagnostic and Theranostic Medicine Division, Paris, France., Schnitt SJ; Department of Pathology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., van Diest PJ; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., Zels G; Department of Oncology, Laboratory for Translational Breast Cancer Research, KU Leuven, Leuven, Belgium; Department of Pathology, University Hospitals Leuven, UH Leuven, Leuven, Belgium., Mertens F; Department of Pathology, University Hospitals Leuven, UH Leuven, Leuven, Belgium., Maetens M; Department of Oncology, Laboratory for Translational Breast Cancer Research, KU Leuven, Leuven, Belgium., Vanden Bempt I; Centre for Human Genetics, University Hospitals Leuven, UH Leuven, Leuven, Belgium., Harbeck N; West German Study Group, Mönchengladbach, Germany; Department of Gynecology and Obstetrics, Breast Center, University of Munich (LMU) and CCCLMU, Munich, Germany., Nitz U; West German Study Group, Mönchengladbach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Mönchengladbach, Germany., Gräser M; West German Study Group, Mönchengladbach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Mönchengladbach, Germany; Department of Gynecology, University Medical Center Hamburg, Germany., Kümmel S; West German Study Group, Mönchengladbach, Germany; Charité - Universitätsmedizin Berlin, Department of Gynecology with Breast Center, Berlin, Germany; Clinics Essen-Mitte, Breast Unit, Essen, Germany., Gluz O; West German Study Group, Mönchengladbach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Mönchengladbach, Germany; University Clinics Cologne, Women's Clinic and Breast Center, Cologne, Germany., Weynand B; Department of Pathology, University Hospitals Leuven, UH Leuven, Leuven, Belgium., Floris G; Department of Pathology, University Hospitals Leuven, UH Leuven, Leuven, Belgium. Electronic address: giuseppe.floris@uzleuven.be., Derksen PWB; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands. Electronic address: P.W.B.Derksen@umcutrecht.nl., Desmedt C; Department of Oncology, Laboratory for Translational Breast Cancer Research, KU Leuven, Leuven, Belgium. Electronic address: christine.desmedt@kuleuven.be.
Jazyk:	angličtina
Zdroj:	Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc [Mod Pathol] 2024 Jul; Vol. 37 (7), pp. 100497. Date of Electronic Publication: 2024 Apr 17.
DOI:	10.1016/j.modpat.2024.100497
Abstrakt:	Invasive lobular carcinoma (ILC) is the second most frequent type of breast cancer (BC) and its peculiar morphology is mainly driven by inactivation of CDH1, the gene coding for E-cadherin cell adhesion protein. ILC-specific therapeutic and disease-monitoring approaches are gaining momentum in the clinic, increasing the importance of accurate ILC diagnosis. Several essential and desirable morphologic diagnostic criteria are currently defined by the World Health Organization, the routine use of immunohistochemistry (IHC) for E-cadherin is not recommended. Disagreement in the diagnosis of ILC has been repeatedly reported, but interpathologist agreement increases with the use of E-cadherin IHC. In this study, we aimed to harmonize the pathological diagnosis of ILC by comparing 5 commonly used E-cadherin antibody clones (NCH-38, EP700Y, Clone 36, NCL-L-E-cad [Clone 36B5], and ECH-6). We determined their biochemical specificity for the E-cadherin protein and IHC staining performance according to type and location of mutation on the CDH1 gene. Western blot analysis on mouse cell lines with conditional E-cadherin expression revealed a reduced specificity of EP700Y and NCL-L-E-cad for E-cadherin, with cross-reactivity of Clone 36 to P-cadherin. The use of IHC improved interpathologist agreement for ILC, lobular carcinoma in situ, and atypical lobular hyperplasia. The E-cadherin IHC staining pattern was associated with variant allele frequency and likelihood of nonsense-mediated RNA decay but not with the type or position of CDH1 mutations. Based on these results, we recommend the indication for E-cadherin staining, choice of antibodies, and their interpretation to standardize ILC diagnosis in current pathology practice. (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu